Healthcare 10 August 2025 - 16 February 2026

CSL shares rebound after neffy nasal spray approval as buyback rolls on
····

CSL shares rebound after neffy nasal spray approval as buyback rolls on

Sydney, February 16, 2026, 17:01 AEDT — The session has ended. CSL Ltd picked up 1.4% by Monday’s close, recouping a slice of last week’s drop. The move followed news that its Seqirus arm secured Australian approval for the neffy adrenaline nasal spray, alongside a fresh update on the company’s share buyback. Shares wrapped up at A$152.17, though that’s still roughly 15.6% below where they stood five sessions ago.
February 16, 2026
OCUL stock spikes 25% after hours as Ocular Therapeutix sets Feb. 17 SOL-1 wet AMD data webcast
···

OCUL stock spikes 25% after hours as Ocular Therapeutix sets Feb. 17 SOL-1 wet AMD data webcast

New York, February 13, 2026, 19:17 EST — After-hours Shares of Ocular Therapeutix surged roughly 25% in after-hours trading Friday, as the company announced when it will reveal topline data from its late-stage wet age-related macular degeneration trial. The stock closed the regular session at $8.88, down 1.9%, but was most recently up 25.2% to $11.12.
February 14, 2026
Why HCA Healthcare stock is up today: Frist family filing, hospital peers rally
·······

Why HCA Healthcare stock is up today: Frist family filing, hospital peers rally

New York, February 11, 2026, 10:54 EST — Regular session Shares of HCA Healthcare climbed 2.4% to $513.88 by late morning on Wednesday, pushing the stock higher alongside a broad uptick in hospital operators. Tenet Healthcare surged 8.4%, Universal Health Services gained 2.7%, and Community Health Systems ticked up 1.7%.
February 11, 2026
Takeda’s $1.7 billion AI drug discovery deal with Iambic: what’s inside the pact
···

Takeda’s $1.7 billion AI drug discovery deal with Iambic: what’s inside the pact

Takeda Pharmaceutical has inked a multi-year deal with Iambic, a private company, to apply AI in small-molecule drug discovery. The agreement could top $1.7 billion in milestone payments and includes royalties on sales. As part of the partnership, Takeda will also gain access to Iambic’s NeuralPLexer software. Reuters Drugmakers are pouring funds into AI tools designed to accelerate early research and trim expenses. These systems focus on identifying which compounds merit development and testing—a critical phase that often consumes years and significant budgets.
February 9, 2026
Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions
········

Drugmakers say AI is shaving weeks off clinical trials and regulatory submissions

Drugmakers are increasingly relying on artificial intelligence to accelerate clinical trials and regulatory filings, slashing weeks off processes that often slow down development, according to executives and analysts. While AI hasn’t yet cracked the code for discovering groundbreaking new drugs, it’s already making a dent in the “messy middle” of drug development. This matters since the timeline remains brutal. Companies report that developing a drug can take around a decade and cost close to $2 billion. Even when results seem promising, the slow grind of trial setup and paperwork can drag timelines out much longer.
January 26, 2026
Yamanaka Factors Are Resetting Aging Cells
······

Rewinding the Clock: How Yamanaka Factors Are Resetting Aging Cells

Imagine if we could press a “reset” button on aging cells, restoring them to a youthful state. Recent breakthroughs in aging biology suggest this might be possible by reprogramming the epigenome – the chemical marks that regulate our DNA – using a set of genes known as the Yamanaka factors. Researchers have found that applying these factors for a short time can roll back cellular aging without completely erasing the cell’s identity scientificamerican.com, sciencedaily.com. The tantalizing hope is that we may reverse age-related damage, improve tissue function, and perhaps even treat diseases of aging by restoring cells to a younger condition. In this report, we’ll explain what the epigenome is and how it changes with age, how Yamanaka factors can
August 18, 2025
Senolytic Drugs
··········

The Secret “Zombie Cell” Killers: Niche Senolytic Drugs Fighting Aging’s Clock

For centuries, people have searched for a fountain of youth. Today, scientists are zeroing in on an intriguing strategy – senolytic drugs – that might help turn back the biological clock. These compounds target the so-called “zombie cells” in our bodies, officially known as senescent cells, which stop dividing but refuse to die nature.com. As we age, these senescent cells accumulate and spew out harmful signals that drive inflammation, tissue damage, and aging itself nature.com. Senolytics are designed to selectively destroy these damaged cells, potentially slowing aging and alleviating many age-related conditions with a single treatment. Researchers discovered the first senolytic breakthrough in 2015, when a Mayo Clinic and Scripps Research team found that a combination of two compounds –
August 17, 2025
How Engineering Nature’s Catalysts is Transforming Medicine, Food & the Planet
··········

The Enzyme Revolution: How Engineering Nature’s Catalysts is Transforming Medicine, Food & the Planet

Imagine if we could reprogram nature’s own microscopic machines to solve human problems. Enzyme engineering is the science of redesigning enzymes – the proteins that catalyze life’s chemistry – to have new or improved functions. In simple terms, it means tweaking an enzyme’s genetic code so the enzyme works better or differently. Why bother? Because enzymes are extraordinary catalysts: they speed up chemical reactions under gentle conditions, unlike many industrial processes that require high heat or toxic chemicals newsroom.uw.edu. As biochemist David Baker explains, “Living organisms are remarkable chemists… they use enzymes to break down or build up whatever they need under gentle conditions. New enzymes could put renewable chemicals and biofuels within reach” newsroom.uw.edu. In other words, if we
August 14, 2025
The Future of Artificial Blood, Organs, and Tissues - Breakthroughs and the Road to Transplantation
·······

Organ failure and blood shortages remain critical challenges in medicine. Over 100,000 patients in the U.S. alone are currently on organ transplant waiting lists, and nearly 20 people die each day unable to receive a transplant in time vox.com. To address this crisis, scientists and biotech innovators are pursuing cutting-edge solutions – from artificial blood cells grown in laboratories, to lab-grown tissues and organoids engineered from stem cells, to even xenotransplantation. These approaches, once the realm of science fiction, have seen remarkable advances in recent years. This report explores the latest scientific developments in artificial blood, tissues, and organoids; the commercialization and regulatory progress toward lab-grown transplants; breakthroughs in xenotransplantation with genetically modified pigs; expert perspectives and ethical considerations; and
August 13, 2025
How Gene Editing Therapies Are Curing the “Incurable”
·····

DNA Makeover: How Gene Editing Therapies Are Curing the “Incurable”

Imagine if doctors could repair a disease at its genetic root, giving patients healthy genes to replace faulty ones. That sci-fi scenario is now real. Patient DNA modification refers to cutting-edge treatments that alter a person’s genetic code to treat or cure illness. These therapies are often called gene therapies or gene editing treatments. Traditional gene therapy usually works by adding a good copy of a gene to make up for a bad one, often using a modified virus as a delivery vehicle. Newer approaches go further – they edit the DNA itself using molecular tools. In short, patient DNA modification means using these molecular tools to correct or compensate for genetic flaws inside a patient’s cells. It’s a radical
August 12, 2025
Organ-on-a-Chip Technology
·······

Lab Rats No More: How Organ-on-a-Chip Technology is Revolutionizing Drug Testing

Every year, over 100 million animals are used in lab experiments worldwide science.rspca.org.uk. Yet despite this scale of animal testing, around 90% of drug candidates that seem promising in animals end up failing in human trials cen.acs.org. Enter organ-on-a-chip technology – a cutting-edge alternative that aims to mimic human organs on microchips and dramatically improve drug testing without the need for lab animals. These tiny devices, lined with living human cells, can recreate the key functions of hearts, lungs, livers, and more, offering a more human-relevant testing platform. Regulators and scientists are taking notice: new laws and policies are encouraging non-animal methods, companies are racing to develop organ-on-chip systems, and experts herald this approach as a potential game-changer for medicine
August 10, 2025
The mRNA Revolution Transforming Medicine
····

Beyond COVID Vaccines: The mRNA Revolution Transforming Medicine

When COVID-19 struck, an unfamiliar technology called mRNA catapulted to global fame with life-saving vaccines developed in record time nobelprize.org. These vaccines, which used messenger RNA to instruct our cells to make virus-fighting proteins, proved about 95% effective and were deployed to billions worldwide nobelprize.org. But the pandemic was just the beginning. Researchers and companies are now unleashing a revolution in medicine powered by mRNA – from personalized cancer treatments to shots for influenza and even therapies for rare genetic diseases. Enthusiasm is high: “The potential implications of using mRNA as a drug are significant and far-reaching,” says Stéphane Bancel, CEO of Moderna mckinsey.com. In this report, we’ll explore what mRNA is, how it works as a drug platform, and
August 10, 2025
1 … 3 4 5 6